Tirofiban for Reduction of Thromboembolic Events in Endovascular Unruptured Aneurysm Repair

Exclusion Criteria

• •1. Abnormal platelet count (normal reference is 100-300×10\^9/L).
• •2. Allergy to study drugs and anesthetics.
• •3. Contradictory to MRI examination.
• •4. Known history of intracranial tumor, arteriovenous malformation, arteriovenous fistula, venous sinus thrombosis, hereditary cerebral small vessel disease, peripheral hemangioma (e.g., aortic aneurysm, limb vascular aneurysm).
• •5. Known history of cerebral parenchymal hemorrhage, subarachnoid hemorrhage, cerebral infarction, transient ischemic attack, or gastrointestinal bleeding within 6 months.
• •6. Clear indications for anticoagulation (presumed cardiac source of embolus, e.g., atrial fibrillation, prosthetic cardiac valves known or suspected endocarditis).
• •7. Antiplatelet drug (exclude aspirin and clopidogrel) being taken within 72 hours; anticoagulant drug (including heparin or oral anticoagulants) being taken within 10 days;
• •8. Participants with recurrent aneurysms who have received neurointerventional treatment.
• •9. Inability to follow endovascular procedures due to anatomical difficulties.
• •10. Severe renal (creatinine exceeding 1.5 times of the upper limit of normal range) or hepatic (ALT or AST \> twice the upper limit of normal range) insufficiency.
• •11. Severe heart failure (NYHA classes III and IV) or severe arrhythmias, including sick sinus syndrome, severe atrioventricular block, and bradycardia-related syncope.
• •12. Pregnant.